Department of Cancer Biology and Genetics, Ohio State University, Columbus, Ohio, USA.
Department of Cancer Biology and Genetics, Ohio State University, Columbus, Ohio, USA; Department of Molecular Genetics, Ohio State University, Columbus, Ohio, USA.
J Invest Dermatol. 2019 Sep;139(9):1857-1859. doi: 10.1016/j.jid.2019.04.009.
The clinical management of large and giant congenital melanocytic nevi (lgCMN) relies heavily upon iterative surgical procedures. In this issue Rouille et al. (2019) use lgCMN explants and a newly developed patient-derived xenograft model to show that the local administration of MEK and Akt inhibitors limits the lgCMN proliferative potential. These findings, along with emerging reports, support continued investigation of targeted therapies in lgCMN.
大/巨大先天性黑素细胞痣(lgCMN)的临床管理主要依赖于反复的手术治疗。在本期中,Rouille 等人(2019 年)利用 lgCMN 外植体和新开发的患者来源异种移植模型表明,局部应用 MEK 和 Akt 抑制剂可限制 lgCMN 的增殖潜能。这些发现以及新出现的报告支持对 lgCMN 进行靶向治疗的进一步研究。